All sponsors

Exelixis $EXEL

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS12
PHASE 3 / 2-310
RECRUITING4
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO62%

Delay Index: of 8 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +15.0 months). See all sponsors →

Open Exelixis on the live radar map → 📅 $EXEL readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Cabozantinib
NCT03690388
P3Active, not recruitingDifferentiated Thyroid Cancer1872020-08-19 (+2 mo)
COSMIC-312
NCT03755791
P3Active, not recruitingHepatocellular Carcinoma8372021-11-30 (+16 mo)
COSMIC-313
NCT03937219
P3Active, not recruitingRenal Cell Carcinoma8552022-01-31 (+3 mo)
CONTACT-02
NCT04446117
P3Active, not recruitingMetastatic Prostate Cancer; Prostate Adenocarcinoma5752024-04-19 (+25 mo)
STELLAR-303
NCT05425940
P3Active, not recruitingColorectal Cancer9012026-06-16 (+10 mo)
STELLAR-304
NCT05678673
P3Active, not recruitingNon-Clear Cell Renal Cell Carcinoma3172026-12-15 (+17 mo)
STELLAR-201
NCT07428616
P2RecruitingMeningioma1002028-02-29
STELLAR-202
NCT07845786
P2RecruitingSquamous Non-Small Cell Lung Cancer (NSCLC)602028-06-15
STELLAR-305
NCT06082167
P2/3Active, not recruitingHead and Neck Squamous Cell Carcinoma6002028-08 (+15 mo)
STELLAR-311
NCT06943755
P2/3RecruitingPancreatic Neuroendocrine Tumor (pNET); Extra-Pancreatic Neuroendocrine Tumor (epNET)4402029-06-30
STELLAR-316
NCT07750158
P3RecruitingColorectal Cancer6002030-04-05
Cabozantinib
NCT07620574
P3Enrolling by invitationCancer; Renal Cell Carcinoma (RCC)50002030-05-31